AstraZeneca is launching a $1.5 billion cost-savings program to fund its drug pipeline
The drugmaker expects one-time restructuring costs of up to $2 billion as it redeploys resources over three years
We haven't written up this one. Quartz has the full story — the link below goes straight to it.